Is Psilocybin Legal in the US? Federal, State, and Clinical Realities Explained
Psilocybin remains illegal under US federal law as a Schedule I substance, but state-level exceptions and clinical research are reshaping access. Here’s what researchers, clinicians, and investors need to know.
Is Psilocybin Legal in the US? The Plain-English Answer
No, psilocybin is not legal for general use in the United States. Under federal law, psilocybin—the psychoactive compound found in so-called "magic mushrooms"—is classified as a Schedule I controlled substance under the Controlled Substances Act (CSA), 21 U.S.C. § 812. This means it is considered to have a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. The US Food and Drug Administration (FDA) has not approved psilocybin for any medical indication as of this writing.
However, there are important exceptions and nuances: certain states (notably Oregon and Colorado) have created legal frameworks for supervised psilocybin services, and psilocybin is the subject of ongoing clinical trials. This is general information and should not be construed as legal advice; consult a qualified attorney for specific guidance.
Federal Law: Schedule I Status and Its Implications
Psilocybin has been a Schedule I substance since the Controlled Substances Act took effect in 1970. Schedule I is the most restrictive category and includes substances such as heroin and LSD. The main legal consequences are:
- Possession, distribution, and manufacture of psilocybin are federal crimes, punishable by fines and imprisonment.
- There are no FDA-approved medical uses for psilocybin outside of clinical trials or research settings with special federal approval.
- Research on psilocybin requires a Schedule I license from the Drug Enforcement Administration (DEA) and must comply with strict federal controls.
For more on how psychedelics are scheduled and regulated, see our Psychedelic Law Guide and Research Landscape Overview.
State-Level Exceptions: Oregon and Colorado
Despite federal prohibition, two states have established legal frameworks for psilocybin services:
Oregon: Measure 109 (2023– )
Oregon became the first US state to legalize supervised adult use of psilocybin through Measure 109, passed by voters in 2020. The program launched in 2023. Under this law:
- Licensed facilitators can administer psilocybin to adults (21+) in regulated service centers.
- Personal possession and unsupervised use remain illegal.
- The program is overseen by the Oregon Health Authority, with strict rules on training, product testing, and client safety.
For more, see our Oregon Psilocybin Services Guide.
Colorado: Proposition 122 (2024–2025)
Colorado voters approved Proposition 122 in 2022, establishing a regulated psilocybin access program. The first supervised sessions are expected to begin in 2024–2025. Key features include:
- Licensed facilitators can provide psilocybin services to adults in approved settings.
- Personal cultivation and sharing are decriminalized, but commercial sales outside the regulated system remain illegal.
Other states and municipalities have decriminalized personal possession or deprioritized enforcement, but these measures do not create legal markets or override federal law.
Clinical Trials and the Path to FDA Approval
Psilocybin is the focus of active clinical research for mental health and other indications. However, no psilocybin product has FDA approval as of now. Two major Phase 3 programs are underway:
- Compass Pathways (COMP360): Conducting Phase 3 trials for treatment-resistant depression, with results expected through 2025–2026.
- Usona Institute (IPR001): Running Phase 3 studies for major depressive disorder.
The FDA has granted "Breakthrough Therapy" designation to some psilocybin programs, signaling strong preliminary evidence and a commitment to expedite review. Recent developments, such as the FDA’s public release of a psychedelic drug framework and regulatory flexibility, suggest the landscape is evolving—but until a product is approved, federal law remains unchanged. For more on the clinical research pipeline, see our Psychedelic Research Landscape and Latest Briefings.
Common Questions About Psilocybin Legality
Can doctors prescribe psilocybin?
No, doctors cannot prescribe psilocybin outside of clinical trials or state-licensed programs in Oregon and Colorado. Unlike MDMA (which recently became prescribable for PTSD), psilocybin remains federally prohibited for all non-research uses.
Is personal use or possession legal anywhere?
Personal use and possession remain federally illegal. Some cities and states have decriminalized or deprioritized enforcement, but these policies do not legalize psilocybin or protect against federal prosecution. Only Oregon and Colorado offer legal supervised use under state law.
Can researchers study psilocybin?
Yes, but only with a Schedule I research license from the DEA and appropriate Institutional Review Board (IRB) oversight. The process is rigorous but increasingly navigable as the FDA and DEA clarify research pathways. For tools and resources, see our Psychedelic Research Tools.
What’s Next? Staying Informed and Navigating the Landscape
The legal status of psilocybin in the US is in flux, with major clinical trials and state-level experiments underway. Federal law remains clear: psilocybin is illegal except for approved research. However, the regulatory climate is shifting, and stakeholders should monitor developments closely.
- For a comprehensive overview, visit our Psilocybin Law and Research Start Page.
- Stay up to date with our Psychedelic Policy Briefings.
- For legal and clinical resources, explore our Guides and Tools.
Always consult legal counsel before engaging in any activity involving psilocybin.